Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis

Authors

  • Roselie Achten Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands
  • Lisa van der Rijst Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands
  • Marjanne Piena OPEN Health, Evidence & Access, Rotterdam, the Netherlands
  • Hedda Lamers Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands
  • Fleur de Beer Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands
  • Marjolein de Bruin-Weller Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands
  • Marlies de Graaf Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands

DOI:

https://doi.org/10.2340/actadv.v103.4842

Keywords:

atopic dermatitis, economic burden, humanistic burden, pediatric, health-related quality of life

Abstract

Data concerning the economic and humanistic burden in patients with paediatric atopic dermatitis (AD) and their families are scarce. This retrospective study investigated these burdens in paediatric patients with AD using maintenance treatment with topical corticosteroids and/or conventional systemic immunosuppressants. Patient-reported outcomes regarding quality of life, AD severity, and parental work-related impairment were completed at inclusion. Data on healthcare resource utilization and medication prescription were collected retrospectively over the previous 12 months. Patients were categorized into mild, moderate or severe AD, based on Eczema Area and Severity Index score and medication use. Costs per patient per year per AD severity category were calculated. A total of 101 patients (median age 11.0 years (interquartile range 7.5–14.0), 47.5% men) were included, of whom 38 had mild AD, 37 moderate AD, and 26 severe AD. Mean ± standard deviation (SD) total costs patient per year for mild, moderate and severe AD were €1,812 ± €1,280, €2,680 ± €3,127, and €5,861 ±  €3,993, respectively. Highest total direct and indirect costs were found in patients with severe AD, mainly due to higher healthcare and medication costs. Highest humanistic burden was found in patients with moderate AD. For example, the median (interquartile range) Patient-Oriented Eczema Measure score was significantly higher in these patients compared with mild and severe AD (19.0 (15.0–24.0) vs 12.0 (8.8–15.0) and 17.0 (9.5–22.0), respectively). AD in paediatric patients incurs considerable direct and indirect costs, especially in patients with severe AD. The high humanistic burden in patients with moderate AD underlines the need for effective and safe new treatment options for children with AD.

Downloads

Download data is not yet available.

Author Biographies

Roselie Achten, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands

Roselie Achten and Lisa van der Rijst contributed equally to this manuscript.

Lisa van der Rijst, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands

Roselie Achten and Lisa van der Rijst contributed equally to this manuscript.

Marlies de Graaf, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands

Corresponding author

References

Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-743.

https://doi.org/10.1016/S0140-6736(06)69283-0 DOI: https://doi.org/10.1016/S0140-6736(06)69283-0

Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol 2020; 100: adv00160.

https://doi.org/10.2340/00015555-3510 DOI: https://doi.org/10.2340/00015555-3510

Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis 2014; 25: 107-114.

https://doi.org/10.1097/DER.0000000000000034 DOI: https://doi.org/10.1097/DER.0000000000000034

Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr 2016; 169: 284-290.e5.

https://doi.org/10.1016/j.jpeds.2015.10.077 DOI: https://doi.org/10.1016/j.jpeds.2015.10.077

Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin 2018; 34: 2177-2185.

https://doi.org/10.1080/03007995.2018.1498329 DOI: https://doi.org/10.1080/03007995.2018.1498329

Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Jr., Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005; 22: 192-199.

https://doi.org/10.1111/j.1525-1470.2005.22303.x DOI: https://doi.org/10.1111/j.1525-1470.2005.22303.x

Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in america study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol 2019; 139: 583-590.

https://doi.org/10.1016/j.jid.2018.08.028 DOI: https://doi.org/10.1016/j.jid.2018.08.028

Olsson M, Bajpai R, Wee LWY, Yew YW, Koh MJA, Thng S, et al. The cost of childhood atopic dermatitis in a multi-ethnic Asian population: a cost-of-illness study. Br J Dermatol 2020; 182: 1245-1252.

https://doi.org/10.1111/bjd.18442 DOI: https://doi.org/10.1111/bjd.18442

Ariens LFM, van Nimwegen KJM, Shams M, de Bruin DT, van der Schaft J, van Os-Medendorp H, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol 2019; 99: 762-768.

https://doi.org/10.2340/00015555-3212 DOI: https://doi.org/10.2340/00015555-3212

Ricci G, Bendandi B, Pagliara L, Patrizi A, Masi M. Atopic dermatitis in Italian children: evaluation of its economic impact. J Pediatr Health Care 2006; 20: 311-315.

https://doi.org/10.1016/j.pedhc.2006.04.009 DOI: https://doi.org/10.1016/j.pedhc.2006.04.009

Weil C, Sugerman PB, Chodick G, Liang H, Wang H, Calimlim BM, et al. Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide Israeli Healthcare Provider Database. Adv Ther 2022; 39: 2502-2514.

https://doi.org/10.1007/s12325-022-02120-6 DOI: https://doi.org/10.1007/s12325-022-02120-6

Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147: 716-724.

https://doi.org/10.1046/j.1365-2133.2002.04964.x DOI: https://doi.org/10.1046/j.1365-2133.2002.04964.x

Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008; 25: 1-6.

https://doi.org/10.1111/j.1525-1470.2007.00572.x DOI: https://doi.org/10.1111/j.1525-1470.2007.00572.x

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44-56.

https://doi.org/10.1001/jamadermatol.2019.3336 DOI: https://doi.org/10.1001/jamadermatol.2019.3336

Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-1293.

https://doi.org/10.1016/j.jaad.2020.06.054 DOI: https://doi.org/10.1016/j.jaad.2020.06.054

Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-2181.

https://doi.org/10.1016/S0140-6736(21)00589-4 DOI: https://doi.org/10.1016/S0140-6736(21)00589-4

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.

https://doi.org/10.1034/j.1600-0625.2001.100102.x DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x

Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.

https://doi.org/10.1111/bjd.15641 DOI: https://doi.org/10.1111/bjd.15641

Guideline for conducting economic evaluations in health care (2015). National Health Care Institute, Diemen. Available from: www.zorginstituutnederland.nl.

Netherlands S. Consumer price index 2018. [accessed Jan 2021] Available from: http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=83131ned.

Medicijnkosten.nl (2017). National Health Care Institute, Diemen. Available from: www.medicijnkosten.nl.

van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010; 69: i89-91.

https://doi.org/10.1136/ard.2009.117150 DOI: https://doi.org/10.1136/ard.2009.117150

Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.

https://doi.org/10.1111/bjd.12590 DOI: https://doi.org/10.1111/bjd.12590

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.

https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513

Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010; 19: 875-886.

https://doi.org/10.1007/s11136-010-9648-y DOI: https://doi.org/10.1007/s11136-010-9648-y

Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949.

https://doi.org/10.1111/j.1365-2133.1995.tb16953.x DOI: https://doi.org/10.1111/j.1365-2133.1995.tb16953.x

Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 1998; 138: 107-113.

https://doi.org/10.1046/j.1365-2133.1998.02034.x DOI: https://doi.org/10.1046/j.1365-2133.1998.02034.x

Haverman L, Grootenhuis MA, Raat H, van Rossum MA, van Dulmen-den Broeder E, Hoppenbrouwers K, et al. Dutch-Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)®. Qual Life Res 2016; 25: 761-765.

https://doi.org/10.1007/s11136-015-0966-y DOI: https://doi.org/10.1007/s11136-015-0966-y

Terwee CB, Roorda LD, de Vet HC, Dekker J, Westhovens R, van Leeuwen J, et al. Dutch-Flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2014; 23: 1733-1741.

https://doi.org/10.1007/s11136-013-0611-6 DOI: https://doi.org/10.1007/s11136-013-0611-6

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.

https://doi.org/10.2165/00019053-199304050-00006 DOI: https://doi.org/10.2165/00019053-199304050-00006

Patient-Reported Outcomes Measurement Information System Anxiety, Dynamic Tools to Measure Health Outcomes From the Patient Perspective, 2015: 1-11.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Strat Soc 1995; 57: 289-300.

https://doi.org/10.1111/j.2517-6161.1995.tb02031.x DOI: https://doi.org/10.1111/j.2517-6161.1995.tb02031.x

IBM Corp. IBM SPSS Statistics for Windows, Version 26.0; IBM Corp.: Armonk, NY, USA, 2019. Available online:

https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-26.

Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-342.

https://doi.org/10.18553/jmcp.2002.8.5.333 DOI: https://doi.org/10.18553/jmcp.2002.8.5.333

Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159-162.

https://doi.org/10.1136/adc.76.2.159 DOI: https://doi.org/10.1136/adc.76.2.159

Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.

https://doi.org/10.1111/jdv.16892 DOI: https://doi.org/10.1111/jdv.16892

Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol 2018; 120: 10-22.e2.

https://doi.org/10.1016/j.anai.2017.10.039 DOI: https://doi.org/10.1016/j.anai.2017.10.039

Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol 2017; 76: 281-285.

https://doi.org/10.1016/j.jaad.2016.09.021 DOI: https://doi.org/10.1016/j.jaad.2016.09.021

Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-232.

https://doi.org/10.1016/j.jaci.2006.02.031 DOI: https://doi.org/10.1016/j.jaci.2006.02.031

Additional Files

Published

2023-03-08

How to Cite

Achten, R., van der Rijst, L., Piena, M., Lamers, H., de Beer, F., de Bruin-Weller, M., & de Graaf, M. (2023). Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 103, adv00881. https://doi.org/10.2340/actadv.v103.4842

Issue

Section

Articles

Categories